Table 1.
Bevacizumab in the first-line setting in metastatic colorectal cancer
| Ref. | Regimen | PFS (mo) | P value | OS (mo) | P value |
| Kabbinavar et al[26]; Phase II | 1Bolus 5-FU/LV ± bevacizumab | 9 vs 5.2 (TTP3) | NA | 21.52 vs 13.8 | NA |
| Kabbinavar et al[27]; Phase II | 1Bolus 5-FU/LV + bevacizumab vs bolus 5-FU/LV + placebo | 9.2 vs 5.5 | 0.0002 | 16.6 vs 12.9 | 0.16 |
| Hochster et al[35]; Phase II (TREE-1) | mFOLFOX6/bFOL/CapeOX | 8.7/6.9/5.9 (TTP3) | N/A4 | 19.2/17.9/17.2 18.2 (overall) | N/A4 |
| Hochster et al[35]; Phase II (TREE-2) | mFOLFOX6 + bevacizumab/bFOL + bevacizumab/CapeOX + bevacizumab | 9.9/8.3/10.3 (TTP3) | 26.1/20.4/24.6 23.7 (overall) | ||
| Hurwitz et al[22]; Phase III | IFL + bevacizumab vs IFL + placebo | 10.6 vs 6.2 | < 0.001 | 20.3 vs 15.6 | < 0.001 |
| Stathopoulos et al[115]; Phase III | IFL ± bevacizumab | NA | NA | 22 vs 25 | 0.1391 |
| Saltz et al[29]; Phase III | FOLFOX/CapeOX + bevacizumab vs FOLFOX/CapeOX + placebo | 9.4 vs 8 | 0.0023 | 21.3 vs 19.9 | 0.077 |
1
Roswell Park regimen: LV 500 mg/m2 over 2 h and FU 500 mg/m2 as a bolus midway through the LV infusion;
2
Data presented is on patients who received chemotherapy plus low-dose bevacizumab;
3
Time to progression;
4
Comparison between outcomes of TREE-1 and TREE-2 is not possible as they were sequential cohorts. 5-FU: 5-Fluorouracil; LV: Leucovorin; PFS: Progression-free survival; OS: Overall survival; mFOLFOX6: Three fluoropyrimidine regimens-infusional 5FU/LV; bFOL: Bolus FU/LV; CapeOX: Capecitabine; FOLFOX: 5-FU/LV/oxaliplatin; NA: Not available; N/A: Not applicable.